Gefitinib offers palliative care for advanced oesophegal cancer
Added: Wednesday 31 October 2012
The drug Gefitinib (Iressa) has not been found to improve survival in advanced oesophegal cancer, but could prove beneficial in a palliative care setting. The researchers are now working on identifying which patients would actually benefit from this. Analysis of biomarkers allows researchers to identify a subgroup of suitable patients. They have warned that using Gefitinib on unselected populations will have no benefit.
In order to be able to see the content from the www.medscape.com pages, please create first a free account at following link: